PA 30.1 - Types, Etiology, Pathogenesis, Hormonal Dependency of Breast Pathology and Benign Disease

Framework: ANDI (Aberrations of Normal Development and Involution)

Etiology & Hormonal Dependency

• Estrogen drives epithelial proliferation and cyst formation; estrogen excess or heightened tissue sensitivity is central to fibrocystic change and cyclical mastalgia
• Progesterone relative deficiency (in the luteal phase) may contribute to stromal edema and mastalgia
• Prolactin may play a permissive role
• Evidence: fibrocystic change is rare in postmenopausal women unless on hormone therapy, and responds to anti-estrogen drugs (tamoxifen, danazol, GnRH analogues) - suggesting tissue hypersensitivity to circulating estrogen even when serum levels are normal

Classification & Types of Benign Breast Disease

1. Fibrocystic Change (Most Common)

• Definition: Spectrum of fibrosis, cyst formation, and epithelial hyperplasia - the most common lesion of the breast
• Etiology: Aberration of normal breast involution; estrogen-dependent
• Pathogenesis: Involution of lobular stroma causes kinking/narrowing of ductules → secretion accumulates → microcysts coalesce into macrocysts; increased epithelial proliferation drives fibrosis
• Epidemiology: Common in women aged 35-55; macroscopic cysts in ~7%, microscopic cysts in ~40% of women; rare after menopause without HRT
• Histology: Fibrosis + cyst formation + epithelial hyperplasia
• Hormonal link: Presence of estrogen appears necessary for clinical symptoms (bilateral distribution, perimenopausal peak, responds to endocrine therapy)
• Cancer risk: Non-proliferative: no increased risk. Proliferative without atypia: 1.5-2x risk. Atypical hyperplasia: 4-5x risk
• Clinical features: Bilateral breast pain, nodularity (especially upper outer quadrant), cyclical in nature, worse premenstrually

2. Fibroadenoma

• Definition: Benign fibroepithelial tumor - most common discrete breast lump in women under 35
• Etiology: Aberration of normal lobular development in the early reproductive phase (15-25 years); lobular proliferation under estrogen stimulation
• Pathogenesis: Both epithelial and stromal elements proliferate under estrogen control; lobular proliferation results in encapsulated nodule with well-defined edges
• Hormonal link: Grows during pregnancy, regresses after menopause, and can enlarge with exogenous estrogen - confirming hormonal dependency
• Macroscopy: Well-circumscribed, rubbery, mobile ("breast mouse"), 1-3 cm
• Histology: Intracanalicular pattern (stroma compresses ducts into slit-like spaces) or pericanalicular pattern (stroma surrounds round ducts)
• Special types:
  • Giant fibroadenoma: >5 cm, especially in adolescents
  • Multiple fibroadenomas: 5 or more lesions
  • Complex fibroadenoma: contains cysts, sclerosing adenosis, epithelial calcifications (slightly elevated cancer risk)
• Cancer risk: Very low (RR ~1.3-1.9 if complex); not a premalignant lesion

3. Intraductal Papilloma

• Definition: Localized hyperplasia of ductal epithelium forming a papillary tumor within the duct
• Structure: Central fibrovascular core with papillary projections of epithelium and myoepithelial cells
• Types and cancer risk:
  • Solitary papilloma - central, large ducts, presents with bloody/serous nipple discharge; RR for cancer ~1.5-2
  • Papillomatosis - 5+ papillomas in multiple ducts, peripheral/bilateral; RR for cancer ~3
  • Juvenile papillomatosis (Swiss cheese disease) - young women, multiple firm nodules, multiple papillomas + apocrine cysts + ductal hyperplasia + sclerosing adenosis; RR higher with family history
• Etiology: Hormonal stimulation of ductal epithelium

4. Epithelial Hyperplasia (Proliferative Breast Disease)

• Definition: >2 cell layers lining ducts or acini
• Types:
  • Hyperplasia without atypia (usual ductal hyperplasia)
  • Atypical Ductal Hyperplasia (ADH) - features of low-grade DCIS but <2 ducts or <2 mm
  • Atypical Lobular Hyperplasia (ALH) - similar to LCIS but involving <50% of acini
• Pathogenesis: Arises from epithelial turnover in the involution phase, driven by estrogen excess
• Cancer risk: ADH/ALH carry 4-5x increased risk (10x if family history present)
• Note: If ADH features involve >2 ducts or >2 mm, the diagnosis becomes DCIS (malignant)

5. Mastalgia (Breast Pain)

• Cyclical mastalgia: Starts around day 14 of cycle, peaks around day 27-28, relieves with menses; usually bilateral; most common form
  • Hormonal basis: responds to anti-estrogens (tamoxifen, ormeloxifene, danazol, GnRH analogues) suggesting excessive breast tissue responsiveness to estrogen, even with normal serum hormone levels
• Non-cyclical mastalgia: Not related to menstrual cycle, usually unilateral, may be from chest wall (Tietze's syndrome, musculoskeletal)
• Affects 50-70% of women attending breast clinics

6. Sclerosing Adenosis

• Benign condition with increased acini per lobule and stromal fibrosis; associated with lobular involution
• Can mimic carcinoma both clinically and mammographically
• Slightly increased cancer risk (RR ~1.5-2) if associated with atypia

7. Duct Ectasia & Periductal Mastitis

• Duct ectasia: Dilatation of subareolar ducts during involution; presents with thick nipple discharge, nipple retraction, or subareolar mass
• Periductal mastitis: Inflammation around dilated ducts; strongly associated with smoking (squamous metaplasia of duct epithelium); can lead to subareolar abscess and mammillary fistula

8. Fat Necrosis

• Etiology: Trauma or surgery to breast adipose tissue
• Pathogenesis: Traumatized fat cells release lipids → inflammatory reaction → fibrosis and calcification
• Clinical concern: Can form a hard, irregular mass with skin tethering, mimicking carcinoma
• Diagnosis: History of trauma + imaging (oil cyst on mammography/US is diagnostic)

9. Breast Abscess & Mastitis

Summary Table: Risk Stratification